Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001:77:195-262.
doi: 10.1016/s0065-2776(01)77018-6.

The antiviral activity of antibodies in vitro and in vivo

Affiliations
Review

The antiviral activity of antibodies in vitro and in vivo

P W Parren et al. Adv Immunol. 2001.

Abstract

This chapter discusses in vitro and in vivo antiviral activities of antibody. Since experimentation is far easier in vitro, researchers have been sought to develop in vitro assays that are expected to predict activity in vivo. This could be important in both vaccine design and in passive antibody administration. The proposed mechanisms of in vitro neutralization range from those requiring binding of a single antibody molecule to virus to those requiring substantially complete antibody coating of virus. In vitro, antiviral activity can be separated into activity against virions and activity against infected cells. The activity against virions most often considered is neutralization that can be defined as the loss of infectivity, which ensues when antibody molecule(s) bind to a virus particle, and occurs without the involvement of any other agency. In vivo, it is conventional to distinguish phenomenologically between two types of antibody antiviral activity. One of them is the ability of antibody to protect against infection when it is present before or immediately following infection. Evidence for a number of viruses in vitro indicates that lower antibody concentrations are required to inhibit infection propagated by free virus than are required to inhibit infection propagated by cell-to-cell spread.

PubMed Disclaimer

References

    1. Arthos J., Deen K.C., Chaikin M.A., Fornwald J.A., Sathe G., Sattentau Q.J., Clapham P.R., Weiss R.A., McDougal J.S., Pietropaolo C., Axel R., Truneh A., Maddon P.J., Sweet R.W. Identification of the residues in human CD4 critical for the binding of HIV. Cell. 1989;57:469–481. - PubMed
    1. Arthur L.O., Bess J.W., Jr., Sowder R.C., II, Benveniste R.E., Mann D.L., Chermann J.-C., Henderson L.E. Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines. Science. 1992;258:1935–1938. - PubMed
    1. Arthur L.O., Bess J.W., Jr., Urban R.G., Strominger J.L., Morton W.R., Mann D.L., Henderson L.E., Benveniste R.E. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J. Virol. 1995;69:3117–3124. - PMC - PubMed
    1. Ashe W.K., Notkins A.L. Kinetics of sensitization of herpes simplex virus and its relationship to the reduction in the neutralization rate constant. Virology. 1967;33:613–617. - PubMed
    1. Ashe W.K., Mage M., Notkins A.L. Kinetics of neutralization of sensitized herpes simplex virus with antibody fragments. Virology. 1969;37:290–293. - PubMed

Publication types

Substances